Drug firm Lupin today announced the launch of pain relief drug Hydrocodone Bitartrate and Acetaminophen in the US market.
In a BSE filing, Lupin announced “the launch of Hydrocodone Bitartrate and Acetaminophen tablets USP, in the strengths of 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.”
In November last year, Lupin said it had received final approval from the US health regulator for its Hydrocodone Bitartrate and Acetaminophen tablets used for providing pain relief.
The company’s product is a generic equivalent of Mikart Inc’s Hydrocodone Bitartrate and Acetaminophen tablets.
According to IMS MAT sales data, product had sales of USD 79.6 million in the US market.
Shares of Lupin were trading 0.48 per cent higher at Rs 1,454.80 on the BSE.